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Abstract
Enthesitis is a common clinical feature of PsA, which is characterized by inflammation at the site of insertion of
tendons, ligaments and joint capsule fibres into bone. Enthesitis is relatively unique to the spondyloarthritides, set-
ting this group of diseases apart from other rheumatological conditions. The pathophysiological underpinnings of
this clinical domain, and the imaging assessment of it, are described in accompanying articles in this supplement.
The focus of this article is on the assessment of enthesitis by physical examination, the impact of enthesitis on
function and quality of life, the impact of concomitant FM on clinical assessment, and the evidence for therapy of
enthesitis garnered in trials of biologic and targeted synthetic DMARDs. Several physical examination measures of
enthesitis have been developed and have proved reliable in assessment of enthesitis. Enthesitis has a significant
deleterious impact on function and quality of life. The presence of concomitant FM in 20% of patients may result
in artefactual worsening of assessment of disease severity and hinder achievement of the goal of low disease ac-
tivity or remission. Several targeted therapies, which, for example, target the TNF, IL-17, IL-23, phosphodiesterase 4
or Janus kinase pathways, have shown significant efficacy in the treatment of enthesitis, resulting in improvement
of function and quality of life for patients with PsA.
Key words: psoriatic arthritis, enthesitis, enthesitis clinical assessment, enthesitis impact, treatment of
enthesitis
Introduction
This article reviews the physical examination measures
that have been developed to assess enthesial tender-
ness, the impact of enthesitis as clinically measured in
long-term observational studies and registries, and the
effect of current and emerging therapies on enthesitis as
assessed in clinical trials.
An important caveat is that the physical examination
measures used in studies and in practice assess
patient-reported tenderness, which may represent true
inflammation at the enthesial site (i.e. enthesitis), but, as
will be discussed, may instead, or at least in part, reflect
the phenomenon of centralized pain, also known by
terms or phrases such as FM, chronic widespread pain
(CWP) or central sensitization syndrome. The fact that
an -itis may not always be present in a tender area is
borne out, in some studies, by lack of correlation with
US or MRI evidence of inflammation. Despite this poten-
tial imprecision of assessment, the clinical indices have
performed fairly well in their ability to discriminate be-
tween active treatment and placebo in clinical trials, as
will be demonstrated.
Several current and emerging therapies are proving to
be highly effective in the treatment of enthesitis.
However, it is important to note that not all treatments
have across-the-board effectiveness in the different clin-
ical domains of PsA (arthritis/synovitis, enthesitis, dacty-
litis, spondylitis, psoriasis skin and nail disease) and,
within a single patient, responsiveness of the different
domains may differ in both magnitude and time of re-
sponse. Thus, it is important to assess each domain in-
dividually, both initially and in follow-up visits, to
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determine quality of treatment. I liken this to a sym-
phony orchestra concert, in which different instruments
and sections may be playing together in concert or as
individual solos at different times, thus emphasizing the
need to listen to the patient, not only about what they
are reporting, but what you as a clinician are picking up
on examination and through imaging and laboratory
evaluation. Given that enthesitis can cause such signifi-
cant pain, physical dysfunction and reduced quality of
life, it is important to work towards a treatment regimen
that can achieve low disease activity or remission in this
domain. Even if, for example, arthritis and skin disease
are well controlled with a given treatment, if significant
enthesitis, documented to be caused by persistent in-
flammation, is stubbornly resistant to that medication,
and physical therapy, injection and surgical approaches
are not helpful or not indicated, then trial of an alterna-
tive medication may need to be pursued.
Enthesitis physical examination indices
The first physical examination approach to enthesitis,
using a standardized index, was the Mander index [1].
This was developed by Mander, a physiatrist in
Newcastle, UK. The Mander index required palpation of
66 enthesial insertion sites. Although comprehensive in
its scope, it proved impractical for use in clinical trials or
practice because of the large number of sites to be
assessed, paucity of routine use by investigators and
other clinicians, and the consequent potential difficulty
of achieving good intra- and inter-rater reliability.
However, it did provide a map for subsequent develop-
ment of simpler clinical indices now used in clinical
trials.
Three enthesitis physical examination indices have
been developed and used in PsA clinical trials and in tri-
als in axial spondyloarthritis (AxSpA), including both
radiographic AxSpA (r-AxSpA), also known as AS, and
non-radiographic AxSpA (nr-AxSpA) (Fig. 1). With each
of the indices, it is recommended that the examiner use
a standardized assessment method for each entheseal
site (e.g. use of the thumb or index finger, applying
enough pressure to blanch the finger about a fifth of the
way from the tip of the fingernail).
The Leeds enthesitis index (LEI) was developed by
Philip Helliwell and others in patients with PsA [1, 2].
The LEI consists of six sites: bilateral lateral epicon-
dyles, medial femoral condyles, and Achilles tendon in-
sertion sites. The LEI is simple to use, because only six
sites are assessed, but in some studies it has lacked
discriminative power because of the small number of
sites assessed.
The Spondyloarthritis Research Consortium of Canada
(SPARCC) index, developed in Canada by Walter
Maksymowych and others, was developed in patients
with spondyloarthritis and includes assessment of 18
sites for tenderness [1, 3]. The total score is 16, because
the distal patella and tibial tuberosity, in close proximity,
are considered as one site. Although only more recently
used in PsA trials, this index has demonstrated consist-
ent ability to discriminate between treatment and pla-
cebo. Recently, studies have used SPARCC plus one (i.e.
having the investigator assess each of the SPARCC
entheseal sites in addition to the medial condyle of the
femur), which then allows calculation of both the
SPARCC and Leeds indices, because the other four sites
of the LEI are included in the SPARCC. This allows for
greater comparability between studies.
The Maastricht ankylosing spondylitis enthesitis score
(MASES), developed in patients with AS, has been used
in AS and AxSpA consistently, with good performance
[1, 4]. It has also been used in some PsA studies and
has demonstrated the ability to discriminate treatment
from placebo in most studies, despite its relative lack of
peripheral entheseal sites, but not in all studies; there-
fore, it is no longer being used in PsA studies. Its per-
formance in studies enriched for patients with PsA
spondylitis has not yet been assessed.
Effect of central sensitization on
assessment of enthesitis
Physical examination detects tenderness. Physical
examination does not discriminate between the true
presence of inflammation (i.e. enthesitis) vs tenderness
attributable to other factors, including what we label
FM/CWP/central sensitization, which are conditions with
overlapping definitions and features. These are relatively
common chronic central pain syndromes, which arise in
individuals with genetic, biological and psychosocial
predisposing factors and are characterized by CWP,
often accompanied by fatigue, sleep disturbance and
other symptoms. These conditions occur more com-
monly in patients with chronic pain and inflammatory
conditions. We might use the term enthesalgia to de-
scribe this phenomenon when it influences tenderness
at entheseal insertion points. It is possible that in some
individuals, tenderness is attributable only to -itis, in
others only to -algia and in others, a combination of the
two.
The phenomenon of coexistent central pain syn-
dromes accompanying chronic rheumatic diseases has
become an item of research and clinical importance be-
cause of its influence on disease severity measures and
determination of treatment response in clinical trials and
in practice. Numerous studies of cohorts of patients
with various rheumatological conditions, including RA,
SLE, SS, OA, PsA and AS, have demonstrated that
15–20% of these cohorts, on average, will have a con-
comitant diagnosis of FM based on various classification
criteria [5]. Brikman et al. [6] noted, in a Tel Aviv cohort
of PsA patients, that concomitant FM was present in
18% and that all of the disease severity measures that
included a subjective element reported by the patient,
such as pain or patient global, such as Disease Activity
in PsA (DAPSA), minimal disease activity (MDA), HAQ
and LEI, were twice as severe as the same measures in
patients without concomitant FM. Højsgaard et al. [7]
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studied 69 PsA patients initiating treatment with physical
and US examination of joints and entheses and also
performed measures for FM/CWP, such as the wide-
spread pain index (WPI) and PainDetect questionnaire.
Responses consistent with FM/CWP on the WPI were
seen in 35%. These patients were not able to achieve a
state of MDA, and there was little correlation between
examination of joints and entheses and US findings.
These findings emphasize the importance of evaluating
patients for concomitant FM/CWP in order to context-
ualize our assessment of disease severity and treatment
response better in individual patients.
Enthesitis in clinical registries
With the above caveats in mind, data on the prevalence,
impact and response to treatment in clinical registries
and clinical trials is reviewed below. Using a modifica-
tion of the SPARCC index, enthesitis is assessed rou-
tinely in the University of Toronto long-term PsA registry
directed by Dafna Gladman. The prevalence of enthesi-
tis in this registry is 35% [8]. Investigators in the
Corrona registry in the USA use the SPARCC and LEI
indices, finding the prevalence of enthesitis in PsA in
this cohort to be 27% [9]. In an analysis of data from
the Corrona registry of 1567 patients with PsA, Mease
observed that patients with enthesitis had significantly
greater disease activity than those without enthesitis,
exemplified by worse severity of arthritis as measured
by the 68 tender and 66 swollen joint counts, higher
DAS28CRP and CDAI scores. Subjects with enthesitis
were less likely to achieve MDA status with PsA treat-
ments. Patients with enthesitis reported higher levels of
pain and fatigue, poorer function and quality of life and
greater impairment at work [9]. Polachek et al. [10] ana-
lysed a group of 223 PsA subjects and noted that
enthesitis, as measured by US, showed a correlation
with more peripheral and axial damage, as measured by
X-ray. Baskan et al. [11] noted a correlation between the
presence of enthesitis and worse quality of life in 52
PsA patients. In 41 PsA patients, a correlation was
noted between poor sleep quality and the presence of
enthesitis, compared with healthy controls [12].
Enthesitis in clinical trials: biologic
treatment
TNF inhibition
The first measurement of enthesitis in PsA therapeutic
trials occurred with infliximab. In IMPACT 2, using a
four-point technique of assessing tenderness of the
Achilles tendon and plantar fascia insertions, a statistic-
ally significant reduction in the presence of enthesitis
was noted at week 12 compared with placebo. In that
study, 30% of patients treated with infliximab demon-
strated Achilles tenderness at baseline compared with
14% at week 12 [13].
Using the same assessment in the adalimumab pivotal
PsA trial, ADalimumab Effectiveness in Psoriatic arthritis
Trial, 38% of patients had evidence of enthesitis at
baseline. Although the mean change in enthesitis score
was greater with adalimumab than with placebo, there
was not a statistically significant separation [14]. Given
subsequent studies, which show adalimumab to have
clear efficacy in treating enthesitis, this result reflects
the fact that the study was not powered to assess
enthesitis, in addition to the limitation of using the four-
point technique.
In the golimumab phase 3 trial, GO-REVEAL, using a
modified MASES index (adding plantar fascia insertion
sites), 75% of patients had evidence of enthesitis at
baseline, and there was a median change of 50% in the
FIG. 1 Three enthesitis indices used in clinical trials
(A) The Leeds enthesitis index (LEI): six sites. (B) The Spondyloarthritis Research Consortium of Canada (SPARCC)
index: 18 sites, with a score of 16. (C) The Maastricht ankylosing spondylitis enthesitis score (MASES): 13 sites.
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approved dose (50 mg) treatment group, statistically su-
perior to placebo at 14 and 24 weeks [15].
In the RAPID-PsA trial, at 24 weeks certolizumab dem-
onstrated significant improvement of enthesitis, noted in
64% of subjects at baseline, using the mean change of
LEI [16].
The etanercept phase 3 study, which was the first of
the TNF inhibitor trials in PsA, did not include an enthe-
sitis measure. The efficacy of etanercept for enthesitis
has been assessed subsequently, most recently in the
SEAM trial, wherein patients with early PsA (median dis-
ease duration of 6 months) were randomized to etaner-
cept or MTX monotherapy or a combination of these
medications [17]. Using the SPARCC index, of 67–69%
with enthesitis at baseline, 53% of the etanercept mono-
therapy group achieved complete resolution of enthesitis
at week 24 and 66% at week 48. In the MTX monother-
apy arm, these percentages were 43 and 51%, respect-
ively. These two arms were statistically separated at
week 48 but not at week 24. A similar degree of im-
provement was seen between the etanercept monother-
apy and combination arms, consistent with other
musculoskeletal outcomes in this study, suggesting that
there was no additional benefit of using this biologic
agent combined with MTX. In this study, the LEI was
also used and showed similar results to the SPARCC.
Although not placebo controlled, the results with MTX
are suggestive that this medication can yield benefit in
the treatment of enthesitis.
Each of these five TNF inhibitors has also been
approved for the treatment of AS (r-AxSpA), and several
have been approved in various countries for nr-AxSpA
[18]. Efficacy of these agents for the treatment of enthe-
sitis in AxSpA has been demonstrated.
IL-12/23 inhibition
The first non-TNF inhibitor to be approved for PsA was
ustekinumab, a p40 IL-12/IL-23 inhibitor. In two pivotal
trials in PsA, PSUMMIT 1 and 2, 70% of subjects had
enthesitis at baseline according to the PsA-modified
MASES (addition of plantar fascia assessment) [19, 20].
The median improvement at 24 weeks in the usual dose
arm (45 mg) was 40% in PSUMMIT 1 and slightly less in
PSUMMIT 2, both significantly separated from placebo.
A small, open label trial studied the effect of ustekinu-
mab in 23 PsA subjects vs infliximab or adalimumab in
24, all of whom had evidence of enthesitis [21]. Using
the SPARCC and MASES indices, ustekinumab showed
statistically superior efficacy compared with the TNF
inhibitors. Significant separation could not be demon-
strated with the LEI, partly because of the low number
of affected sites at baseline using that index. In a
phase 3 trial programme, ustekinumab did not show effi-
cacy in the treatment of AxSpA [22]. This result came as
a surprise, because an earlier open label trial had sug-
gested potential efficacy [23]. Whether ustekinumab
could be effective in peripheral enthesitis in AxSpA is
unclear. These results suggest that there might be differ-
ential effectiveness between peripheral enthesitis, as
seen in the PsA trial results, and the enthesial compo-
nent of axial disease [24].
IL-17 inhibition
Two IL-17A inhibitors have been approved for the treat-
ment of PsA, secukinumab and ixekizumab, and one IL-
17A and F inhibitor, bimekizumab, is in development for
psoriasis and PsA.
Using a four-point scoring technique, 61% of patients
in FUTURE 1, in which an i.v. loading dose of secukinu-
mab was used, followed by monthly s.c. injections, had
evidence of enthesitis at baseline [25]. At week 24, 46%
of these patients demonstrated complete resolution of
enthesitis. In FUTURE 2, in which an s.c. loading dose
(the currently approved regimen) was followed by
monthly s.c. dosing, of the 60% at baseline demon-
strating enthesitis, 48 and 42% treated with 300 and
150 mg of secukinumab, respectively, demonstrated
complete resolution of enthesitis [26]. As patients were
tracked out to 104 weeks, the percentage demonstrating
complete resolution increased to 70% in the various
arms of the study. In FUTURE 5, the largest study to
date in PsA (996 patients), of the 60% with enthesitis at
baseline per LEI assessment, 65 and 53% in the 300
and 150 mg arms, respectively, achieved complete reso-
lution of enthesitis at week 24 [27]. In FUTURE 5, the
SPARCC index was also performed and displayed per-
formance characteristics similar to the LEI. Owing to the
robustness of these results, there are several studies
underway to investigate the effect of secukinumab in
studies focused on enthesitis, using not only clinical but
also US and/or MRI assessment.
In the SPIRIT-P1 study of biologic-naı¨ve PsA patients,
enthesitis was present at baseline in 58% of subjects [28].
The mean change of LEI score showed numerical but not
statistically significant improvement in the ixekizumab-
treated patients compared with placebo at 24 weeks.
Statistical significance compared with placebo was dem-
onstrated in a post hoc analysis of complete resolution of
enthesitis assessed by LEI in 40% of the patients in the
study arms. In a TNF inhibitor-exposed PsA population in
SPIRIT-P2, 56% had enthesitis at baseline and, of these,
35% displayed complete resolution using LEI. This did
not achieve statistical significance vs placebo at week 24,
the primary end point, but it did at earlier time points.
In the first trial comparing two biologics head to head
in the treatment of PsA, SPIRIT H2H, ixekizumab was
compared with adalimumab in an open-label, assessor-
blinded approach [29]. Enthesitis was present in slightly
>60% of patients as assessed by the SPARCC index.
At week 24, 57% of patients treated with ixekizumab
demonstrated resolution of enthesitis, whilst 45%
treated with adalimumab did so, a statistically significant
separation. Similar improvement was demonstrated
using the LEI, although not statistically separated.
In the phase 2B BE-ACTIVE trial of bimekizumab, an
IL-17A and F inhibitor, 50% of the patients demon-
strated enthesitis according to LEI at baseline. At
12 weeks, two 160 mg dose arms, with and without a
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loading dose, demonstrated 59% complete resolution of
enthesitis vs 29% in the placebo group, a statistically
significant separation.
Secukinumab is approved for the treatment of AS/
r-AxSpA. Ixekizumab has shown efficacy in a
phase 3 group of studies in this indication, and
bimekizumab is also being developed for this indi-
cation, for which enthesitis is an important clinical
domain.
IL-23 inhibition
Three p19 IL-23 inhibitors are in development for PsA:
guselkumab, risankizumab and tildrakizumab.
Guselkumab enthesitis data were reported in a
phase 2 trial, in which 57% of patients with enthesitis
demonstrated LEI complete resolution compared with
29% in the placebo group, a statistically significant dif-
ference [30].
In a phase 2 trial of risankizumab, 65% of subjects
had enthesitis according to the SPARCC index at
baseline; statistically significant improvement in two
of five risankizumab dose arms was noted at week 24
[31].
Partial data from a phase 2 study of tildrakizumab has
been reported [32]. Approximately 50% of subjects had
evidence of enthesitis at baseline according to LEI as-
sessment; all dose arms showed numerical mean
change differentiation from placebo at week 24 but
achieved statistical differentiation only in the highest
dose group of 200 mg every 4 weeks.
A clinical trial of risankizumab in AxSpA failed to show
efficacy [33].
T-cell modulation
Abatacept, a T-cell modulator that inhibits T-cell activa-
tion through a co-stimulatory blockade mechanism, is
approved for PsA [34]. In a phase 3 study, 65% of
patients had enthesitis at baseline. Of these, 33%
achieved LEI resolution compared with 21% in the pla-
cebo group at week 24, a numerical but not statistically
significant difference. Abatacept is not effective for the
treatment of AxSpA.
IL-6 inhibitor
Although IL-6 inhibition is not a mechanism that is in
current development for PsA, an exploratory phase 2
study with a direct IL-6 inhibitor, clazakizumab, was
performed in PsA. In that study, >75% of subjects
had evidence of enthesitis at baseline, using both
SPARCC and LEI assessments [35]. The SPARCC
index demonstrated numerical improvement in all
clazakizumab treatment arms compared with pla-
cebo at week 24. Of note, the LEI was not able to
discriminate between the treatment arms and pla-
cebo. IL-6 inhibition is not effective for the treatment
of AxSpA.
Enthesitis in clinical trials: targeted
synthetic disease modification
There are two oral medications that have been approved
for the treatment of PsA, apremilast and tofacitinib, and
numerous others in the development pipeline [36].
These are known as targeted synthetic DMARDs
(tsDMARDs), because their mechanism of action targets
specific immunological mechanisms more precisely than
older oral medications, such as MTX, SSZ and LEF,
which are known as conventional synthetic DMARDs
(csDMARDs). Some patients may prefer oral over paren-
teral administration of medication, partly related to the
lack of need for refrigeration while travelling. Also, there
is no immunogenicity with an oral medication, which can
sometimes lead to loss of efficacy with the parenterally
administered biologic agents.
Phosphodiesterase 4 inhibition
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor,
which, by inhibiting PDE4, modulates intracellular signal
transduction, decreases conversion of cyclic adenosine
monophosphate to adenosine monophosphate and, by
this mechanism in immunologically active cells, results
in less pro-inflammatory cytokine production. In
PALACE-1, a phase 3 trial in PsA, enthesitis was noted
at baseline in >60% of patients using the MASES [36].
The mean change of the MASES score was statistically
higher in apremilast-treated patients than placebo at
week 16, and at week 24 statistically more apremilast-
treated patients achieved resolution of MASES.
Apremilast has not shown efficacy in AxSpA.
Janus kinase inhibition
Tofacitinib, a Janus kinase (JAK) inhibitor, is approved
for treatment of PsA. Enthesitis was assessed in two
pivotal phase 3 studies, OPAL Broaden and OPAL
Beyond, the former with biologic-naı¨ve patients and the
latter with patients who had had lack of efficacy or in-
tolerance of at least one TNF inhibitor [37, 38]. In OPAL
Broaden, at month 3, the mean change in LEI in the 61–
71% who had enthesitis at baseline was significantly
greater than placebo for the 10 mg twice daily dose but
not for the approved 5 mg twice daily dose. However, in
OPAL Beyond, both doses of tofacitinib demonstrated
statistically significant improvement compared with pla-
cebo at month 3 in the 63–75% of patients who had
enthesitis at baseline.
Several other JAK inhibitors are actively in develop-
ment for PsA, including filgotinib and upadacitinib, which
are both relatively specific for JAK1 inhibition. In the
EQUATOR trial, 59 and 74% in the filgotinib and pla-
cebo arms, respectively, had enthesitis at baseline
according to SPARCC and LEI assessment [39]. At
week 16, of those with enthesitis, 35% achieved
SPARCC resolution in the treatment arm and 23% in
placebo, and the similar percentages for LEI resolution
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were 52 and 26%, respectively, which were statistically
significant separations. Data from the upadacitinib de-
velopment programme are expected soon. Several other
JAK inhibitors, customized for differing JAK selectivities,
are anticipated to be studied in PsA in the near future.
These agents are also demonstrating efficacy in AxSpA
clinical development.
Enthesitis in OMERACT core domain and
core assessment sets
The Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis (GRAPPA)-OMERACT has identi-
fied enthesitis as part of the core domain and assess-
ment set of PsA [40]. At present, the GRAPPA group
considers each of the indices for assessment of enthesi-
tis as valid and feasible, although in more recent trials,
the SPARCC and LEI are the most commonly used indi-
ces to assess enthesitis. The SPARCC has reliably
shown ability to discriminate between treatment and
placebo and response to treatment. The LEI has gener-
ally performed well, but in a few trials it has shown less
discriminatory capability, partly owing to the smaller
number of sites assessed, although for this same rea-
son, it may be easier to use in clinical settings. A formal
analysis of these performance characteristics will be
forthcoming as part of the OMERACT core set of out-
come measures for PsA.
Enthesitis in treatment recommendations
Treatment guidelines developed by prominent inter-
national and dermatology associations highlight the im-
portance of assessing and effectively treating enthesitis
as one of the core clinical domains of PsA (GRAPPA
[41], EULAR [42], ACR/National Psoriasis Foundation
[43] and American Academy of Dermatology [44]). The
approach of the GRAPPA group is to evaluate the evi-
dence for therapy of each major clinical domain (periph-
eral arthritis, enthesitis, dactylitis, axial disease, skin and
nail disease) and recommend treatments that have pro-
ven efficacy in each domain. For enthesitis, for example,
based on the paucity of evidence for effectiveness of
csDMARDs, the recommendation is to go from NSAID
therapy directly to biologic or tsDMARD therapy. The
fact that enthesitis is singled out for assessment and
treatment in each of these guidelines emphasizes the
need for the clinician to do so in day-to-day practice.
Future directions
Recognition of the unique clinical presentation and sig-
nificant patient impact of enthesitis in PsA has led to
increased research on the pathophysiology of this do-
main, which will continue to burgeon. More research is
needed regarding the accurate assessment of inflamma-
tion in the enthesium (i.e. distinguishing -itis from -algia),
including detailed studies to correlate clinical evaluation
with advanced imaging assessment (e.g. US, MRI and
other modalities). Additionally, it is hoped that serum
biomarkers can be identified that will help with the as-
sessment of enthesitis. As new treatments emerge, as-
sessment of their impact on enthesitis will be a core
part of clinical trials.
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